MULTIPLE MYELOMA

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas for multiple myeloma and what will come next now that this data set has been made available.

Topline results from the MajesTEC-9 study showed superior progression-free survival and overall survival for teclistamab in patients with 1 to 3 prior lines of treatment for multiple myeloma.

A single-cell atlas of patients with multiple myeloma has identified specific immune signatures that predict patient outcomes and treatment responses beyond traditional cytogenetic risk factors.

The FDA clears KLN-1010, a groundbreaking in vivo gene therapy for relapsed multiple myeloma, enhancing CAR-T treatment accessibility and efficacy.

Research uncovers distinct sex-based differences in exosomal ncRNA dysregulation in multiple myeloma, highlighting the need for personalized treatment strategies.

Heather Cooper Ortner leads the International Myeloma Foundation, focusing on advancing research, improving patient access, and enhancing support for myeloma care.

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for relapsed patients.

Trial results in multiple myeloma at the 2025 ASH Annual Meeting provide potential practice-changing paradigm shifts.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of CAR T-cell therapy.

FDA grants a priority voucher for Tec-Dara, showcasing significant survival benefits in relapsed/refractory multiple myeloma, enhancing treatment options.

A real-world analysis highlights elranatamab's effectiveness in relapsed multiple myeloma, showcasing response rates and survival outcomes compared with teclistamab.

A novel all-antibody therapy shows remarkable efficacy and safety in elderly patients with newly diagnosed multiple myeloma, achieving high response rates and MRD negativity.

GC012F/AZD0120 CAR T-cell therapy shows 100% response rate in newly diagnosed multiple myeloma, offering hope for diverse patient groups.

New data reveals that the BPd treatment combination significantly improves outcomes in relapsed multiple myeloma, outperforming traditional therapies.

The MonumenTAL-2 study reveals promising results for talquetamab and pomalidomide in treating relapsed/refractory multiple myeloma, showcasing high response rates.

KLN-1010 shows promising MRD-negative responses in relapsed/refractory multiple myeloma patients, highlighting its potential as a safe, off-the-shelf CAR T therapy.

The LimiTEC trial reveals that discontinuing teclistamab after 6-9 months yields comparable outcomes to continuous treatment in multiple myeloma patients.

The MagnetisMM-30 trial reveals promising early responses and manageable safety for elranatamab and iberdomide in relapsed multiple myeloma patients.

Cilta-cel shows promising long-term survival rates in relapsed/refractory multiple myeloma, suggesting potential for a cure in standard-risk patients.

Bispecific antibodies talquetamab and teclistamab show promising results in treating relapsed/refractory multiple myeloma with extramedullary disease, achieving high response rates.

AZD0120 demonstrates impressive early efficacy and safety in treating relapsed/refractory multiple myeloma, with a 96% response rate and rapid manufacturing.

Linvoseltamab shows promising efficacy and safety as a monotherapy for newly diagnosed multiple myeloma, offering a simpler treatment alternative.

Cevostamab shows promising efficacy and manageable safety in treating relapsed/refractory multiple myeloma, offering a convenient subcutaneous administration option.

Gintemetostat shows promising efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

New research reveals KRd therapy significantly enhances progression-free survival in newly diagnosed multiple myeloma compared to traditional VRd treatment.